telegraphindia.com:8080/116...
A notification issued by the Central Board of Excise and Customs withdrawing the exemption of basic customs duty on 76 drugs is likely to increase the retail prices of imported versions of these medicines, industry analysts and patients' rights activists have said.
The drugs include anti-cancer agents, including decarbazine, gemcitabine, imatinib mesylate, procarbazine, paclitaxel, and trastuzumab, two drugs used to treat neurological conditions, nitroglycerine used to treat heart disorders, among other drugs.